Reconstitution of lyophilised peptides: difference between revisions
Diff·revision 20 → 21·19:17, 18 Apr 2025
Difference between revision 20 and revision 21 of Reconstitution of lyophilised peptides. 7 lines changed; the page grew by 854 bytes.
| Revision 20 — 16:33, 31 Mar 2025 HyphenHarriet (talk) correct the unit conversion — U-100 not U-40 4,389 bytes ±0 | Revision 21 — 19:17, 18 Apr 2025 GramsNotUnitsGil (talk) serial comma per PP:MOS 5,243 bytes +854 | ||
|---|---|---|---|
| 37 | Volumes drawn from the resulting solution are governed by [[Insulin syringe|syringe]] graduations, which are marked in insulin units rather than in millilitres. See [[Insulin syringe unit conversion]].{{r|usp1503}} | 37 | Volumes drawn from the resulting solution are governed by [[Insulin syringe|syringe]] graduations, which are marked in insulin units rather than in millilitres. See [[Insulin syringe unit conversion]].{{r|usp1503}} |
| 38 | 38 | ||
| + | 39 | == Storage after reconstitution == | |
| + | 40 | A reconstituted solution has a much shorter usable life than the powder it came from. Degradation routes that are negligible in the dry solid — deamidation, oxidation, aggregation, and microbial growth where no preservative is present — all operate.{{r|ich_q1a}} | |
| + | 41 | ||
| + | 42 | Refrigeration slows chemical degradation substantially: rate constants for deamidation and oxidation fall several-fold between ambient and 2–8 °C. Freezing a reconstituted peptide solution is generally counterproductive, since ice formation concentrates solutes and creates interfaces, and repeated freeze–thaw is a well-documented cause of aggregation.{{r|manning2010}} | |
| + | 43 | ||
| 39 | == References == | 44 | == References == |
| 40 | {{reflist}} | 45 | {{reflist}} |
| ⋮ | ⋮ | ||
| 42 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 47 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 43 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> | 48 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> |
| + | 49 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | |
| 44 | 50 | ||
| 45 | == See also == | 51 | == See also == |
| ⋮ | ⋮ | ||
| 49 | * [[Beyond-use date]] | 55 | * [[Beyond-use date]] |
| 50 | * [[Peptide aggregation]] | 56 | * [[Peptide aggregation]] |
| + | 57 | * [[Reconstitution calculator]] | |
| 51 | 58 | ||
| 52 | {{DEFAULTSORT:Reconstitution of lyophilised peptides}} | 59 | {{DEFAULTSORT:Reconstitution of lyophilised peptides}} |